given to 68 patients, some of whom are described elsewhere.' Although the introduction of thrombolytic treatment reduced the annual number of pulmonary embolectomies this operation was performed in 41 of 109 patients with acute massive pulmonary embolism. Sixteen patients (39%) had a definite contraindication to thrombolytic treatment (major surgery within the last week (n = 10), pregnancy (n = 2), haemorrhagic eye disease (n = 1), active gastrointestinal bleeding (n = 1), active ulcerative colitis (n = 1), and lung cavitation (n = 1) and 13 (32%) were considered to be too ill for a trial of streptokinase. Two patients (5%) started on streptokinase but they deteriorated and were referred for operation. A further five (12%) patients had undergone a major operation 8-14 days before their acute massive pulmonary embolism, and in the early days of our experience with thrombolysis we regarded this as a relative contraindication. In four patients (10%) thrombolytic treatment could have been given but pulmonary embolectomy was regarded as the best treatment.
Acute massive pulmonary embolism is a life threatening disorder that must be treated immediately. Some believe that there are no indications for embolectomy' while others justify prophylactic open embolectomy.' This debate was particularly intense in the early 1970s once thrombolytic treatment was shown to hasten the resolution of pulmonary emboli.34 Although we often use thrombolytic agents to manage patients with acute massive pulmonary embolism we continue to refer patients for pulmonary embolectomy. We report the indications for this operation and our experience of its use in 71 patients.
Patients and results
Between 1964 and 1986 a total of 139 patients were admitted to the Brompton Hospital with acute massive pulmonary embolism. Until 1968 heparin was the only available drug and therefore all 30 patients with acute massive pulmonary embolism admitted during this period had pulmonary embolectomy. After 1968 streptokinase became available and was
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Accepted for publication 31 May 1988 given to 68 patients, some of whom are described elsewhere.' Although the introduction of thrombolytic treatment reduced the annual number of pulmonary embolectomies this operation was performed in 41 of 109 patients with acute massive pulmonary embolism. Sixteen patients (39%) had a definite contraindication to thrombolytic treatment (major surgery within the last week (n = 10), pregnancy (n = 2), haemorrhagic eye disease (n = 1), active gastrointestinal bleeding (n = 1), active ulcerative colitis (n = 1), and lung cavitation (n = 1) and 13 (32%) were considered to be too ill for a trial of streptokinase. Two patients (5%) started on streptokinase but they deteriorated and were referred for operation. A further five (12%) patients had undergone a major operation 8-14 days before their acute massive pulmonary embolism, and in the early days of our experience with thrombolysis we regarded this as a relative contraindication. In four patients (10%) thrombolytic treatment could have been given but pulmonary embolectomy was regarded as the best treatment.
So over 23 years 71 pulmonary embolectomies were performed (49 women, mean age 39 4 years, range 17-68 and 22 men, mean age 51-2 years, range Inevitably some patients will die before or during transfer but a significant number with acute massive pulmonary embolism will deteriorate some hours after the initial embolic episode27 suggesting that although the risk of death declines with time it is not abolished. This has certainly been our experience; most patients in our series were transferred from other hospitals and were still severely compromised haemodynamically.
Although it has proved difficult to define these patients who are considered too ill to undergo a trial of thrombolytic treatment this does not deny their existence and 32% of the patients in this series belonged to would have fared if they had not had embolectomy. But we believe that it was of benefit.
Morbidity in patients undergoing pulmonary embolectomy was principally neurological. In most this damage was believed to have occurred before operation, usually as a result of a cardiac arrest. The outcome was good in patients who reached the operating theatre without needing external cardiac massage. Although most patients were not given long term anticoagulants the frequency of recurrent pulmonary emboli in the follow up period was low (4-6%). This accords with the view that long term anticoagulants are unnecessary" and that for patients who have an isolated episode of massive pulmonary embolism procedures to plicate or place filters in the inferior vena cava are inappropriate. These procedures should probably be reserved for the few patients who have recurrent pulmonary emboli and in whom oral anticoagulation is either contraindicated or fails to prevent recurrence. 233 We use thrombolysis to treat acute massive pulmonary embolism unless such drugs are contraindicated or haemodynamic function is severely compromised. We believe pulmonary embolectomy provides an effective alternative treatment with an acceptable mortality in these two groups and in those who deteriorate on thrombolytic treatment.
